2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
8
Rituximab
7
fludarabine
6
dacetuzumab
6
fludarabine phosphate
5
blinatumomab
4
Bortezomib
4
ibrutinib
3
Melphalan
3
Lenalidomide
3
Ifosfamide
3
Etoposide
3
Dexamethasone
3
Bendamustine Hydrochloride
3
AP 1903 reagent
3
ponatinib
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Tacrolimus
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Doxorubicin
2
Carboplatin
2
Busulfan
2
Brentuximab Vedotin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Immunoproliferative Disorders
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled